ETF recommends updating COVID-19 vaccines to target new LP.8.1 variant | European Medicines Agency (EMA)
Updated vaccines will help maintain protection against disease as virus continues to evolve
Related Articles
Implementation of surgical site infection prophylaxis in children – a cross sectional prospective study
Surgical Site Infections (SSI) are a common cause for morbidity and mortality in both adults and children. In paediatric surgery, evidence on specific prevention measures…
Nach Gletschersturz in der Schweiz droht weitere Gefahr
Das Bergdorf Blatten in der Schweiz ist nach einem Gletschersturz großteils verschüttet worden, eine Person wird noch vermisst. Die Behörden geben keine Entwarnung, denn durch…
Phage DisCo: targeted discovery of bacteriophages by co-culture | mSystems
In this work, we describe a targeted phage discovery method that allows immediate isolation of phages with specific traits. Currently, to find a phage with…
Office Hours with Earth’s Virology Professor Livestream 5/28/25 8 pm ET
Join Vincent Racaniello for Office Hours to answer your questions about viruses – including SARS-CoV-2, Mpox virus, poliovirus, influenza virus, and more – o…
Autophagy-mediated downregulation of AXL and TIM-1 promotes sustained Zika virus infection | PNAS
Zika virus (ZIKV) infection can lead to a variety of clinical outcomes, including severe congenital abnormalities. The phosphatidylserine receptors…
HHS cancels nearly $600 million Moderna contract on vaccines for flu pandemics
HHS has notified Moderna that it is canceling a nearly $600 million contract for vaccines for flu strains that could trigger future pandemics.
MAD-ID
Contagion® is a news resource for infectious disease specialists and practitioners, aiding identification, diagnosis, treatment and prevention.
Cambodia logs fourth fatal H5N1 avian flu case of the year
Reports of human H5N1 cases from Cambodia have been on the rise since the end of 2023.
Novel antibiotics for gonorrhea get funding boost
Two novel antibiotic candidates for gonorrhea received funding to advance into clinical trials.
Roche to launch phase 3 trial for new antibiotic targeting Acinetobacter baumannii
The Swiss drugmaker says the safety and efficacy of zosurabalpin will be investigated in a study involving 400 patients with carbapenem-resistant A baumannii infections.